Population pharmacokinetics and dose optimization of voriconazole in patients with COVID-19-associated pulmonary aspergillosis.

ABSTRACT:

Objectives

The study aimed to investigate the pharmacokinetic profile of voriconazole in patients with COVID-19-associated pulmonary aspergillosis (CAPA) to optimize dosing strategies.

Methods

Population pharmacokinetic modeling was conducted using clinical data from CAPA patients to analyze voriconazole's pharmacokinetic behavior. A one-compartment model with first-order elimination was employed to characterize voriconazole disposition. Covariate analysis was further utilized to evaluate the impact of continuous renal replacement therapy (CRRT) and select biochemical markers on voriconazole clearance.

Results

The model estimated voriconazole's apparent clearance (CL/F) at 3.17 L/h and apparent volume of distribution (V/F) at 135 L for a standard patient with CAPA. Co

SUBMITTER: Wang H 

PROVIDER: S-EPMC12014539 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature